AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03384459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the 308-nm excimer laser
Description: For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
Study NCT03184883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single conventional denture
Description: mandibular conventional denture with soft liner
Study NCT03184883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single flexible denture
Description: mandibular flexible compete denture
Study NCT03504891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI prior to CRT Upgrade
Description: We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
Study NCT03504891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI prior to de novo CRT
Description: We will perform MRI prior to de novo CRT implants as the comparison group.
Study NCT02822742 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DE-117 ophthalmic solution
Study NCT06445465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1216
Description: \[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
Study NCT03986242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rolling
Description: use non- vibration rolling and the total time is 20 minutes.
Study NCT03986242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration rolling
Description: use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
Study NCT03986242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static stretching
Description: static stretching and the total time is 20 minutes.
Study NCT02822742 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost ophthalmic solution 0.005%
Study NCT03283488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
Study NCT03283488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol
Description: Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
Study NCT02146053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulfate
Description: ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
Study NCT02208596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Study NCT02146053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules: methyl cellulose
Study NCT01253369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT02287857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domestic Tenofovir Disoproxil Fumarate Tablets
Description: 1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
Study NCT02287857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate Tablets of Gilead
Description: 1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
Study NCT04635150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Close Collaboration with Parents
Description: Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
Study NCT01658605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1605786
Description: 500 mg twice daily administered orally
Study NCT01658605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500 mg twice daily administered orally
Study NCT01569737 — intervention group
Intervention type: DRUG
Intervention: ella
Description: ella, single intake, tablet 30mg
Study NCT03232827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flavored-Sweetened Waterpipe Tobacco
Description: Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
Study NCT03232827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unflavored-sweetened waterpipe tobacco
Description: Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
Study NCT03232827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unflavored-very low sweetened waterpipe tobacco
Description: Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
Study NCT03232827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flavored-very low sweetened waterpipe
Description: Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
Study NCT03522415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
Study NCT03522415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate（MTX）
Description: Methotrexate is a slow-acting antirheumatic drug.
Study NCT03522415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate（MTX）
Description: Methotrexate is a slow-acting antirheumatic drug.
Study NCT00773643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
Study NCT03114111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminolevulinic acid (ALA)
Study NCT03114111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01648023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo
Study NCT01648023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gem-Cis or Gem-Carbo
Study NCT01876680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and aerobic exercise
Description: Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year.
Study NCT01876680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year.
Study NCT01896778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia Treatment
Description: Undergo B-WARM
Study NCT01989819 — intervention group
Intervention type: OTHER
Intervention: skin biopsy
Study NCT01896778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01236261 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Description: Non interventional study
Study NCT04620616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
Study NCT04620616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
Study NCT03984838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
Description: JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
Study NCT00708903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study NCT00708903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00708903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT01436695 — intervention group
Intervention type: DEVICE
Intervention: Epicall
Description: The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
Study NCT01595438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime - Avibactam ( CAZ-AVI)
Description: Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
Study NCT01595438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doripenem
Description: 500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
Study NCT01595438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Study NCT01595438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Study NCT01595438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Study NCT01595438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Study NCT05191732 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma; Bone marrow concentrate
Description: Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
Study NCT01000025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-00299804
Description: PF-804 45 mg PO, daily
Study NCT01000025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 45 mg PO, daily
Study NCT01716026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevazizumab intravitreal injection
Description: Intravitreal injection of bevacizumab
Study NCT04508010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR
Description: Participants will receive an IVR survey
Study NCT01716026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevazizumab intravitreal injection
Description: Intravitreal injection of bevacizumab
Study NCT03001323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degludec
Description: Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above.
Study NCT03001323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard long-acting
Description: Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above.
Study NCT04620616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject Usual Brand ENDS
Description: Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
Study NCT02452710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Open-label placebo
Study NCT02829008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose-bevacizumab/pemetrexed
Description: Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
Study NCT02829008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of physician's choice
Description: The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
Study NCT00651313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
Study NCT00651313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal gel administered once daily for 4 days
Study NCT00143988 — intervention group
Intervention type: BEHAVIORAL
Intervention: Treadmill testing
Description: Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
Study NCT00143988 — intervention group
Intervention type: BEHAVIORAL
Intervention: Ambulatory Blood Pressure and Heart Rate Monitoring
Description: Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
Study NCT01612442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition and agricultural education
Description: Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
Study NCT01612442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
Study NCT04508010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CATI
Description: Participants will receive a CATI survey
Study NCT00005808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin lutetium
Description: Given IV
Study NCT00005808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo laser therapy
Study NCT00005808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop electrosurgical excision procedure
Description: Undergo LEEP
Study NCT00005808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00101153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00101153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00101153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Study NCT03393689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
Description: One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
Study NCT01320813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted thyroidectomy
Description: Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
Study NCT01320813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open thyroidectomy
Description: Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
Study NCT01422603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
Study NCT01422603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
Study NCT00377104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00377104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00377104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01821404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Capsules including 80 mg of atorvastatin
Study NCT01821404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar capsules as in the atorvastatin arm, but without the active ingredient
Study NCT01613508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach
Study NCT01613508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Posterior Approach
Study NCT00647946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir DF
Description: tenofovir DF 300mg once daily along with the other antiviral drugs
Study NCT00647946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir 300mg twice daily
Description: abacavir 300mg twice daily along with the other antiviral drugs
Study NCT01040689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744) Low
Description: Low dose inhaled orally once daily from Respimat inhaler
Study NCT00005969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT00005969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin Liposome
Description: Liposome by vein (IV) over 30 minutes every other day for 28 days
Study NCT01757587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: 50 mg, 2 tablets/day on 3 months, both periods of treatment
Study NCT01757587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg 2 tablets / day on 3 months, both periods of treatment